The Benchmark Company slashes price target on Seelos Therapeutics Inc. [SEEL] – find out why.

Seelos Therapeutics Inc. [NASDAQ: SEEL] closed the trading session at $1.29 on 06/15/20. The day’s price range saw the stock hit a low of $1.16, while the highest price level was $1.35. The stocks have a year to date performance of -3.73 percent and weekly performance of 12.17 percent. The stock has been moved at 11.21 percent over the last six months. The stock has performed 74.32 percent around the most recent 30 days and changed 173.65 percent over the most recent 3-months.

If compared to the average trading volume of 1.30M shares, SEEL reached to a volume of 1829637 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Seelos Therapeutics Inc. [SEEL]:

The Benchmark Company have made an estimate for Seelos Therapeutics Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on November 14, 2019. The new note on the price target was released on May 14, 2019, representing the official price target for Seelos Therapeutics Inc. stock.

The Average True Range (ATR) for Seelos Therapeutics Inc. is set at 0.14, with the Price to Sales ratio for SEEL stock in the period of the last 12 months amounting to 131.45. The Price to Book ratio for the last quarter was 6.45, with the Price to Cash per share for the same quarter was set at 0.31.

SEEL stock trade performance evaluation

Seelos Therapeutics Inc. [SEEL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.17. With this latest performance, SEEL shares gained by 74.32% in over the last four-week period, additionally plugging by 11.21% over the last 6 months – not to mention a drop of -41.89% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SEEL stock in for the last two-week period is set at 66.90, with the RSI for the last a single of trading hit 67.05, and the three-weeks RSI is set at 64.97 for Seelos Therapeutics Inc. [SEEL]. The present Moving Average for the last 50 days of trading for this stock 0.7923, while it was recorded at 1.1720 for the last single week of trading, and 0.9527 for the last 200 days.

Seelos Therapeutics Inc. [SEEL]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Seelos Therapeutics Inc. [SEEL] shares currently have an operating margin of -7399.20. Seelos Therapeutics Inc.’s Net Margin is presently recorded at -13668.00.

Return on Total Capital for SEEL is now -2,163.51, given the latest momentum, and Return on Invested Capital for the company is -3,996.49. Return on Equity for this stock declined to -3,996.49, with Return on Assets sitting at -690.02.

Reflecting on the efficiency of the workforce at the company, Seelos Therapeutics Inc. [SEEL] managed to generate an average of -$8,542,500 per employee.Seelos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.00.

Earnings per share (EPS) analysis for Seelos Therapeutics Inc. [SEEL] stock

With the latest financial reports released by the company, Seelos Therapeutics Inc. posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 30.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SEEL.

Seelos Therapeutics Inc. [SEEL]: Insider Ownership positions

There are presently around $6 million, or 12.40% of SEEL stock, in the hands of institutional investors. The top three institutional holders of SEEL stocks are: UNIPLAN INVESTMENT COUNSEL, INC. with ownership of 2,069,121, which is approximately 211.391% of the company’s market cap and around 7.20% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 1,078,379 shares of the stock with an approximate value of $1.28 million in SEEL stocks shares; and SABBY MANAGEMENT, LLC, currently with $0.6 million in SEEL stock with ownership of nearly New of the company’s market capitalization.

Positions in Seelos Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 17 institutional holders increased their position in Seelos Therapeutics Inc. [NASDAQ:SEEL] by around 2,516,308 shares. Additionally, 9 investors decreased positions by around 148,819 shares, while 8 investors held positions by with 2,517,823 shares. The mentioned changes placed institutional holdings at 5,182,950 shares, according to the latest SEC report filing. SEEL stock had 8 new institutional investments in for a total of 946,847 shares, while 6 institutional investors sold positions of 104,651 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download free eBook for 



Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.